Top

Published in:

01-11-2018 | Original Article

Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients

Authors: Yekaterina O. Ostapchuk, Yuliya V. Perfilyeva, Elena A. Kustova, Natalya T. Urazalieva, Nazgul A. Omarbaeva, Shynar G. Talaeva, Nikolai N. Belyaev

Published in: Breast Cancer | Issue 6/2018

Abstract

Background

Regulatory T cells (Tregs) play a major role in tumor escape from immunosurveillance by suppressing effector cells. The number of Tregs is increased in tumor sites and peripheral blood of breast cancer patients. However, the data regarding phenotypic and functional heterogeneity of Treg subpopulations in breast cancer are limited. The present study aimed to investigate the number and suppressive potential of Tregs that possess natural naïve-(N nTregs), effector/memory-like (EM nTregs), and Tr1-like phenotypes in breast cancer patients and healthy women.

Methods

The study included 10 HW and 17 primary breast cancer patients. Numbers of CD4⁺CD25⁺FoxP3⁺CD45RA⁺ N nTregs, CD4⁺CD25⁺FoxP3⁺CD45RA⁻ EM nTregs, and CD4⁺IL-4⁻IL-10⁺ Tr1 subsets and the expression of CTLA-4, CD39, GITR, LAP, and IL-35 by these Treg subsets were measured in freshly obtained peripheral blood by flow cytometry.

Results

Herein, we demonstrate that the percentages of N nTregs, EM nTregs, CD25⁺ and FoxP3⁺ Tr1 cells are elevated in the peripheral blood of breast cancer patients, but do not correlate with cancer stages. Nevertheless, the frequency of CD25⁺ Tr1 cells was associated with nodal involvement, while the number of EM nTregs correlated with clinical outcome. The expression of CTLA-4 and IL-35 by all assessed Treg subsets was increased throughout all tumor stages (I–III).

Conclusions

Collectively, the current study shows phenotypic alterations in suppressive receptors of Treg subsets, suggesting that breast cancer patients have increased activity of N nTregs, EM nTregs and Tr1 cells; and EM nTregs and CD25⁺ Tr1 cells represent prospective markers for assessing disease prognosis.

Stewart BW, Wild CP. World cancer report 2014. World Health Organ 2014:1–2

Zou W. Regulatory T, cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295–307. https://doi.org/10.1038/nri1806.CrossRefPubMed

Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636–45. https://doi.org/10.1016/j.immuni.2009.04.010.CrossRefPubMed

Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol. 2013;4:190. https://doi.org/10.3389/fimmu.2013.00190.CrossRefPubMedPubMedCentral

Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev. 2001;182:68–79. https://doi.org/10.1034/j.1600-065X.2001.1820105.x.CrossRefPubMed

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899–911. https://doi.org/10.1016/j.immuni.2009.03.019.CrossRefPubMed

Booth NJ, McQuaid AJ, Sobande T, Kissane S, Agius E, Jackson SE, et al. Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J Immunol. 2010;184(8):4317–26. https://doi.org/10.4049/jimmunol.0903781.CrossRefPubMed

Watanabe MA, Oda JM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer Metastasis Rev. 2010;29(4):569–79. https://doi.org/10.1007/s10555-010-9247-y.CrossRefPubMed

Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211–8.PubMed

10.

Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating FoxP3+ regulatory T cells. Clin Cancer Res. 2008;14(8):2413–20. https://doi.org/10.1158/1078-0432.CCR-07-4491.CrossRefPubMed

11.

Zhou Y, Shao N, Aierken N, Xie C, Ye R, Qian X, et al. Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis. J Cancer. 2017;8:4098–105. https://doi.org/10.7150/jca.21030.CrossRefPubMedPubMedCentral

12.

Gol-Ara M, Jadidi-Niaragh F, Sadria R, Azizi G, Mirshafiey A. The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis. Arthritis. 2012;2012:805875. https://doi.org/10.1155/2012/805875.CrossRefPubMedPubMedCentral

13.

Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, et al. Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Sci Rep. 2016;6:39247. https://doi.org/10.1038/srep39247 CrossRefPubMedPubMedCentral

14.

Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606–12. https://doi.org/10.1158/1078-0432.ccr-05-1244.CrossRefPubMed

15.

Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016;4(3):28. https://doi.org/10.3390/vaccines4030028.CrossRef

16.

Beyer M, Classen S, Endl E, Kochanek M, Weihrauch MR, Debey-Pascher S, et al. Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FoxP3. Clin Dev Immunol. 2011;2011:734036. https://doi.org/10.1155/2011/734036.CrossRefPubMedPubMedCentral

17.

Abo-Elenein A, Elgohary SE, Hashish A, El-Halaby E. Significance of immunoregulatory T cells in different stages of breast cancer. Egypt J Immunol. 2008;15(2):145–52.PubMed

18.

Liyanage UK, Moore TT, Joo H, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756–61. https://doi.org/10.4049/jimmunol.169.5.2756.CrossRefPubMed

19.

Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG, Shevach EM. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood. 2009;113(21):5125–33. https://doi.org/10.1182/blood-2009-01-199950.CrossRefPubMedPubMedCentral

20.

Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. Interleukin-35-mediated induction of a novel regulatory T cell population. Nat Immunol. 2010;11(12):1093–101. https://doi.org/10.1038/ni.1952.CrossRefPubMedPubMedCentral

21.

Mahalingam J, Lin C-Y, Chiang J-M, Su PJ, Chu YY, Lai HY, et al. CD4+ T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer. PLoS One. 2014;9(9):e108554. https://doi.org/10.1371/journal.pone.0108554.CrossRefPubMedPubMedCentral

22.

Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, et al. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immun. 2012;42(7):1876–85. https://doi.org/10.1002/eji.201142347.CrossRef

23.

Cai XY, Wang XF, Li J, Dong JN, Liu JQ, Li NP, et al. Overexpression of CD39 and high tumoral CD39+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. Int J Clin Exp Pathol. 2015;8(11):14757–64.PubMedPubMedCentral

24.

Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, et al. Interleukin-35 limits anti-tumor immunity. Immunity. 2016;44(2):316–29. https://doi.org/10.1016/j.immuni.2016.01.013.CrossRefPubMedPubMedCentral

25.

Syed Khaja AS, Toor SM, El Salhat H, Faour I, Ul Haq N, Ali BR, et al. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget. 2017;8(20):33159–71. https://doi.org/10.18632/oncotarget.16565.CrossRefPubMed

26.

Krausz LT, Fischer-Fodor E, Major ZZ, Fetica B. GITR-expressing regulatory T-cell subsets are increased in tumor-positive lymph nodes from advanced breast cancer as compared to tumor-negative lymph nodes. Int J Immunopathol Pharmacol. 2012;25(1):59–66. https://doi.org/10.1177/039463201202500108.CrossRefPubMed

27.

Perfilyeva Y, Ostapchuk Y, Aktas Cetin E, Yilmaz A, Deniz G, Talaeva S, et al. Hyaluronan-binding T regulatory cells in peripheral blood of breast cancer. Clin Cell Immunol. 2015;6(1):286. https://doi.org/10.4172/2155-9899.1000286.CrossRef

28.

Hamidinia M, Ghafourian Boroujerdnia M, Talaiezadeh A, Solgi G, Roshani R, Iranprast S, Khodadadi A. Increased P-35, EBI3 transcripts and other Tregs markers in peripheral blood mononuclear cells of breast cancer with different clinical stages. Adv Pharm Bull. 2015;5:261–267. https://doi.org/10.15171/apb.2015.036.CrossRefPubMedPubMedCentral

29.

Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013;19(6):739–46. https://doi.org/10.1038/nm.3179.CrossRefPubMed

30.

Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008;14(12):3706–15. https://doi.org/10.1158/1078-0432.CCR-07-5126.CrossRefPubMedPubMedCentral

31.

Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, Girolomoni G. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol. 2000;114(2):295–302. https://doi.org/10.1046/j.1523-1747.2000.00881.x.CrossRefPubMed

32.

Chen J, Chen Z. The effect of immune microenvironment t on the progression and prognosis of colorectal cancer. Med Oncol. 2014;31:82. https://doi.org/10.1007/s12032-014-0082-9.CrossRefPubMed

33.

Adalid-Peralta L, Fragoso G, Fleury A, Sciutto E. Mechanisms underlying the induction of regulatory T cells and its relevance in the adaptive immune response in parasitic infections. Int J Biol Sci. 2011;7(9):1412–26. https://doi.org/10.7150/ijbs.7.1412.CrossRefPubMedPubMedCentral

34.

Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 2012;133(1):11–21. https://doi.org/10.1007/s10549-011-1855-x.CrossRefPubMed

35.

Chen G, Liang Y, Guan X, Chen H, Liu Q, Lin B, et al. Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosis in breast cancer. Am J Transl Res. 2016;8(5):2255–64.PubMedPubMedCentral

36.

Ostapchuk YO, Cetin EA, Perfilyeva YV, Yilmaz A, Skiba YA, Chirkin AP, et al. Peripheral blood NK cells expressing HLA-G, IL-10 and TGF-β in healthy donors and breast cancer. Cell Immunol. 2015;298(1–2):37–46. https://doi.org/10.1016/j.cellimm.2015.09.002.CrossRefPubMed

37.

Deeb N, Mehanna RA. Assessment of maturation status of tumor-infiltrating dendritic cells in invasive ductal carcinoma of the breast: relation with vascular endothelial growth factor expression. Turk Patol Derg. 2013;29(3):193–200. https://doi.org/10.5146/tjpath.2013.01186.CrossRef

38.

Gregori S, Goudy KS, Roncarolo MG. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol. 2012;3:30. https://doi.org/10.3389/fimmu.2012.00030.CrossRefPubMedPubMedCentral

Title: Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients
Authors: Yekaterina O. Ostapchuk
Yuliya V. Perfilyeva
Elena A. Kustova
Natalya T. Urazalieva
Nazgul A. Omarbaeva
Shynar G. Talaeva
Nikolai N. Belyaev
Publication date: 01-11-2018
Publisher: Springer Japan
Published in: Breast Cancer / Issue 6/2018
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-018-0874-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Comprehensive immunohistochemical analyses on expression levels of hedgehog signaling molecules in breast cancers

Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation

Acknowledgements to reviewers 2018

Impact of visual feedback on dose-volume histograms for organs at risk in postoperative radiotherapy with deep inspiration breath-holding for patients treated with breast-conserving therapy: a planning study

Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence

Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer